Corvus Pharmaceuticals, INC Schedule 13G passive stakes

State Street Corporation has disclosed beneficial ownership of 5.3% of Corvus Pharmaceuticals Inc.'s common stock as of June 30, 2026.

Point72 Asset Management and Steven A. Cohen have reported a 0% beneficial ownership stake in Corvus Pharmaceuticals, Inc. as of March 31, 2026.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 7.5% of Corvus Pharmaceuticals, Inc. common stock issuable upon warrant exercise.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting 0% beneficial ownership in Corvus Pharmaceuticals Inc. due to an internal realignment.

Richard A. Miller and related entities disclose beneficial ownership of 7.8% of Corvus Pharmaceuticals, Inc. common stock.

The Vanguard Group has reported a 5.18% beneficial ownership stake in Corvus Pharmaceuticals Inc., held as a passive investment.

BlackRock, Inc. has reported a beneficial ownership of 5.4% of Corvus Pharmaceuticals Inc.'s common stock.

Samlyn Capital, LLC, Samlyn, LP, and Robert Pohly have reported a complete divestment of their beneficial ownership in Corvus Pharmaceuticals, Inc., now holding 0% of common stock.

Samlyn Capital, LLC, along with Samlyn, LP and Robert Pohly, has filed an Amendment No. 4 to Schedule 13G, reaffirming a 6.0% beneficial ownership stake in Corvus Pharmaceuticals, Inc. as of March 31, 2025.

Samlyn Capital, LLC, along with Samlyn, LP and Robert Pohly, has reported a 9.8% beneficial ownership stake in Corvus Pharmaceuticals, Inc., totaling 6,667,105 shares of common stock as of December 31, 2024.

Dr. Richard A. Miller, a key figure at Corvus Pharmaceuticals, Inc., has increased his beneficial ownership in the company to 7.7% as of December 31, 2024, according to a recent Schedule 13G/A filing.